I'm mage

MAIL STOP - PCT Docket No.: 27549U

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: KAUTZ

Art Unit: UNKNOWN

Appl. No.: 10/589,082

Examiner: UNKNOWN

Appl. Filing Date: August 11, 2006

Confirmation No.: UNKNOWN

Intl. Appl. No.: PCT/EP2005/050708

Intl. Appl. Filing Date: February 17, 2005

For: NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES
AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS

### TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1. Supplemental Information Disclosure Statement;
- 2. Supplemental PTO Form-1449 with 26 references cited; and
- 3. Copies of 22 of the 26 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted, THE NATH LAW GROUP PLLC

February **\mathbb{Y}**, 2007

Gary M/ Nath/Reg. No. 26,965

Sheldon M. McGee, Reg. No. 50,454

Customer No. 34375

Le

MAIL STOP - PCT

Docket No.: 27549U

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: KAUTZ Art Unit: UNKNOWN

Appl. No.: 10/589,082 Examiner: UNKNOWN

Appl. Filing Date: August 11, 2006 Confirmation No.: UNKNOWN

Intl. Appl. No.: PCT/EP2005/050708

Intl. Appl. Filing Date: February 17, 2005

For: NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES

AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### Sir:

A Supplemental Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- a. [XXX] The enclosed supplemental statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- b. [ ] The enclosed supplemental statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed supplemental statement is accompanied by [check one]:

- [ ] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
- [] ii. a check in the amount required by 37 C.F.R. 1.17(p).

c.	[	] The enclosed supplemental statement is being filed
		after the mailing date of a final action under 37 C.F.R.
		1.113, or a notice of allowance under 37 C.F.R. 1.311,
		but before payment of the issue fee.

- [ ] Certification report(e) below; and
- [ ] a check in the amount as required by 1.17(p).
- d. [ ] The enclosed supplemental statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.
- e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]
  - I hereby certify that each item of information contained in the enclosed Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

I hereby certify that no item of information in the enclosed Supplemental Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

or

- [ ] Appropriate certification is attached.
- f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XXX] Copies of the documents are attached herewith with a completed Supplemental PTO Form-1449.

or

[ ] Copies of the documents are not attached, with a completed Supplemental PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

# and / or

[XXX] Copies of US Patents/Publications not attached, with a completed Supplemental PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Supplemental PTO Form-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Supplemental PTO Form-1449, and return a copy of the initialed Supplemental PTO Form-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted, THE NATH LAW GROUP PLLC

February **%**, 2007

Gary M. Nath, Reg. No. 26,965

Sheldon M/McGee, Reg. No. 50,454

Customer No. 34375

MAIL STOP - PCT Docket No.: 27549U

SUPPLEMENTAL PTO\_FORM-1449

# INFORMATION DISCLOSURE

htor: KAUTZ

ppl. No.: 10/589,082

Art Unit: UNKNOWN

Examiner: UNKNOWN

CITATION DISCLOSURE			Appl. Filing Date: August 11, 2006			Examiner: UNKNOWN		
						Confirm. No.: UNKNOWN		
			บ. ร	. PATENT DOCUME	NTS			
Exam. Initial		Document No.		Issue/Public. Date		Inventor	Filed Date	
	A1	6,121,279		19 Sep 2000		Gutterer	18 Jul 1998	
	A2	6,127,378		03 Oct 2000		Gutterer	24 Mar 1997	
	A3	6,191,138		20 Feb 2001		Gutterer	30 Jan 1997	
	A4	6,410,551		25 Jun 2002		Gutterer	18 Jul 1998	
	A5							
			FORE	IGN PATENT DOCUM	ŒNTS			
Exam. Initial		Document No.		Public. Date		Country	Translation	
Initial	A6	97/35854 A	1	02 Oct 1997	<del> </del> -	WO	abstract	
	A7	00/42034 A1		20 Jul 2000	<del> </del>	WO	n/a	
	A8	02/06238 A1		24 Jan 2002	<del>                                     </del>	WO	n/a	
	A9	2005/090311 A1		29 Sep 2005	<del> </del>	WO	n/a	
	A10	2005/085225 A1		15 Sep 2005	1	WO	n/a	
	A11	2005/084104 A2		15 Sep 2005		WO	n/a	
	A12	2005/085203 A1		15 Sep 2005	<del>                                     </del>	WO	n/a	
	A13	2005/087745 A1		22 Sep 2005	<del> </del>	WO	n/a	
	A14	2005/087744 A1		22 Sep 2005	<del> </del>	WO	n/a	
	A15	2006/092422 A1		08 Sep 2006	<del>                                     </del>	WO	n/a	
·	A16	00/42020 A1		20 Jul 2000		WO	n/a	
	A17	99/05111 A1		04 Feb 1999		WO	n/a	
	A18	00/42018 A1		20 Jul 2000		WO	n/a	
	A19	97/28131 A1		07 Aug 1997	+	WO	abstract	
	A20	99/05113 A1		04 Feb 1999	<del> </del> -	WO	n/a	
	A21	00/42019 A		20 Jul 2000		WO	n/a	
	A22	02/06270 A1		24 Jan 2002		WO	n/a	
	A23	00/42017 A1		20 Jul 2000	WO		n/a	
	A24	00,1202.		20 041 2000		.,,		
		1.		OTHER	4			
Exam. Initial		(1	ncluding	Author, Title, Date,	Pert	inent Pages, etc.)		
	"Souness, J.E., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors". Immunopharmacology, Vol. 47, pg. 127-162, 2000".							
	A26	"Dyke, H.J., "Update on the therapeutic potential of PDE4 inhibitors".  Expert Opinion on Investigational Drugs, Vol. 11, No. 1, pg. 1-13, 2002".						
·	A27	"Montana, J., "Chapter 5. Phosphodiesterase 4 Inhibitors". Annual Reports Med Chem, Vol. 36, pg. 47-56, 2001.						
	A28	"Schmidt, B.J., "The phosphodieseterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis". Allergy Clin Immunol, Vol. 108, pg. 530-536, 2001".						
	A29				•			
xaminer	•	<u>*</u>			ΙΓ	ate Considered	}	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.